Optometry 360
  • Home
  • Conferences
  • Videos
  • About Us
    • About Us – Mission
    • Media Partners
    • Advisory Board
    • Industry Council
    • Business Team

What are you looking for?

  • Conference Roundup
  • Contact Lenses
  • Diagnostics
  • Glaucoma
  • Myopia
  • Neurotrophic Keratitis
  • Ocular Surface Disease
  • Pediatrics
  • Practice Management
  • Presbyopia
  • Retina
  • Spotlight Series
The evolving role of the optometrist in nonsurgical cataract management
Optometry 360
  • Home
  • Conferences
  • Videos
  • About Us
    • About Us – Mission
    • Media Partners
    • Advisory Board
    • Industry Council
    • Business Team
Home > Preservative-free bimatoprost matches preserved formulation in glaucoma and OHT
  • Glaucoma

Preservative-free bimatoprost matches preserved formulation in glaucoma and OHT

Kelsey Moroz

Preservative-free bimatoprost 0.01% ophthalmic gel provided intraocular pressure (IOP) lowering comparable to BAK-preserved bimatoprost 0.01% solution in patients with open-angle glaucoma or ocular hypertension, according to a pooled analysis of two Phase 3 trials.

The analysis included 951 patients with controlled IOP at screening who were randomized after washout to receive either preservative-free bimatoprost 0.01% (n = 468) or preserved bimatoprost 0.01% (n = 483 ) once daily for 84 days. Investigators assessed mean IOP change from 8 am, 10 am, and 4 pm at baseline, week 6, and week 12.

Both treatments produced similar reductions in IOP across all time points. Preservative-free bimatoprost achieved reductions of 31% to 35% compared with 32% to 36% for the preserved formulation. Differences in IOP lowering between groups remained under 1.0 mm Hg throughout the 12-week treatment period.

There were fewer treatment-related ocular adverse events in the preservative-free group compared with the preserved group (23.8% vs 27.6%). The most common adverse events were conjunctival hyperemia and eye irritation. Investigators also noted numerical trends favoring the preservative-free formulation for conjunctival hyperemia and corneal fluorescein staining at both weeks 6 and 12.

Reference

Bacharach J, Miller-Ellis E, Harasymowycz P, et al. Efficacy and Safety of Preservative-Free Bimatoprost 0.01% Gel in Patients with Open-Angle Glaucoma and Ocular Hypertension: Results from Two Phase III Randomized Trials. Clin Ophthalmol. 2026;20:571715. doi: 10.2147/OPTH.S571715. PMID: 42004641; PMCID: PMC13086034.

Share

Related Content

  • Glaucoma

Large wearable study examines physical activity and sleep in adults with glaucoma

  • Glaucoma

Optometrists expand role in glaucoma care worldwide, but barriers remain

  • Glaucoma

Global glaucoma disability rates decline despite rising case burden

  • Glaucoma

Adults with ASD show higher rates of glaucoma, cataract, and other eye conditions

  • Glaucoma

Cognitive function and comorbidity linked to different glaucoma medication adherence barriers

  • Glaucoma

AOA 2026: Surgical and technological advances to improve quality of life and reduce drop burden in glaucoma

Share

Advisory Board

Kaleb Abbott, OD, MS, FAAO

Clark Chang, OD

Jessica Haynes, OD, FAAO, FORS, Dipl ABO

Monica Kalia, OD

Cecelia Koetting, OD, FAAO, DipABO

Roya Attar, OD, MBA, DHA, FAAO

Hardeep Kataria, OD, FAAO

Marc R. Bloomenstein, OD, FAAO

Elise Kramer, OD

See All
Optometry 360

Optometry 360® is a dynamic digital platform dedicated to advancing the field of eye care.

Get to Know Us

  • Home
  • About Us
  • Media Partners
  • Advertising Policy
  • Our Advisory Board

Sign up for our Newsletter

Sign up for our Newsletter to get our newest articles instantly!

  • Privacy Policy
  • Advertising Policy
  • Medical Disclaimer
IHM Logo

© 2026 Optometry 360 is a trademark of International Healthcare Media, LLC. All rights Reserved

  • MedJournal360 Icon
  • RareDisease360 Icon
  • MyHero360 Icon
  • Optometry360 Icon
  • Ophthalmology360 Icon